Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Xospata (gilteritinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Astellas

Drug class:

Multi-tyrosine kinase inhibitor

Related drugs:

‹

›

FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: A1 - Approval gilteritinib Sensitive : A1	gilteritinib Sensitive: A1 - Approval gilteritinib Sensitive : A1
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: A2 - Guideline gilteritinib Sensitive : A2	gilteritinib Sensitive: A2 - Guideline gilteritinib Sensitive : A2
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: A2 - Guideline gilteritinib Sensitive : A2	gilteritinib Sensitive: A2 - Guideline gilteritinib Sensitive : A2
FLT3-ITD mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
WT1 mutation	Acute Myelogenous Leukemia	WT1 mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
BRAF mutation	Acute Myelogenous Leukemia	BRAF mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
CBL mutation	Acute Myelogenous Leukemia	CBL mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
KRAS mutation	Acute Myelogenous Leukemia	KRAS mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
GATA2 mutation	Acute Myelogenous Leukemia	GATA2 mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B